Lyell Immunopharma, Inc. (NASDAQ:LYEL) Director Purchases $116,000.00 in Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) Director Sumant Ramachandra acquired 200,000 shares of the stock in a transaction that occurred on Friday, March 21st. The stock was purchased at an average cost of $0.58 per share, with a total value of $116,000.00. Following the completion of the acquisition, the director now owns 200,000 shares of the company's stock, valued at $116,000. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Lyell Immunopharma Stock Performance

Shares of Lyell Immunopharma stock traded down $0.05 during trading hours on Friday, reaching $0.54. The company's stock had a trading volume of 615,131 shares, compared to its average volume of 1,060,268. Lyell Immunopharma, Inc. has a one year low of $0.48 and a one year high of $3.15. The company's 50 day simple moving average is $0.61 and its 200 day simple moving average is $0.86. The stock has a market cap of $159.78 million, a P/E ratio of -0.69 and a beta of -0.41.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last issued its earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.52). The business had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. On average, sell-side analysts predict that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.

Remove Ads

Institutional Investors Weigh In On Lyell Immunopharma

A number of hedge funds have recently added to or reduced their stakes in the stock. Centiva Capital LP acquired a new stake in shares of Lyell Immunopharma in the 3rd quarter worth about $31,000. Graham Capital Management L.P. acquired a new stake in shares of Lyell Immunopharma in the fourth quarter valued at approximately $33,000. RPO LLC bought a new stake in shares of Lyell Immunopharma during the fourth quarter valued at approximately $42,000. Intech Investment Management LLC acquired a new position in shares of Lyell Immunopharma during the third quarter worth approximately $52,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Lyell Immunopharma in the 3rd quarter worth approximately $52,000. 66.05% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a "neutral" rating and issued a $1.00 target price on shares of Lyell Immunopharma in a research report on Thursday, March 13th.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.